Evidence map›Paper›PMID 35350988›Full record

Trial reportBMC cardiovascular disorders2022

Use of levosimendan combined with Shenfu injection to treat acute heart failure patients with hypotension: a prospective randomized controlled single-blind study.

Miaomiao Li, Yue Zhang, Qianli Wan, Yiou Li, Tianzhen Qu, Fang Yuan

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cardiovascular disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Miaomiao Li *Department of Critical Care Medicine (Specialty of Heart Failure), Tongren Hospital Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Shanghai, 200050, China.
Yue Zhang *Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Qianli WanDepartment of Critical Care Medicine (Specialty of Heart Failure), Tongren Hospital Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Shanghai, 200050, China.
Yiou LiDepartment of Critical Care Medicine (Specialty of Heart Failure), Tongren Hospital Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Shanghai, 200050, China.
Tianzhen QuDepartment of Critical Care Medicine (Specialty of Heart Failure), Tongren Hospital Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Shanghai, 200050, China.
Fang YuanDepartment of Critical Care Medicine (Specialty of Heart Failure), Tongren Hospital Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Shanghai, 200050, China. yfangBM@163.com.
Shanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLevosimendan can improve clinical symptoms and the cardiorenal rescue success rate, and stabilize hemodynamic parameters in individuals suffering from acute decompensated heart failure. In addition, Shenfu injection (SFI) has been shown to protect the ischemic heart and enhance myocardial contractility.

methodsFor this randomized control single-blind study, 101 patients with acute decompensated heart failure (ADHF) were enrolled and randomly assigned to control levosimendan (n = 51) and levosimendan + SFI injection (n = 50) groups. Attending physicians were not blinded for which arm the patients were allocated. Blood pressure, heart rate, the electrocardiogram, respiratory rate, fluid intake and urine output were all recorded 2 h and 24 h after drug infusions had commenced, and the cardiac index (CI) was monitored by ultrasonic cardiac output monitors.

resultsMedian blood pressure was markedly increased in the levosimendan + SFI group after 2 h and 24 h from the initiation of infusions compared to levosimendan administration alone. Brain natriuretic peptide (BNP) concentrations were reduced after administrations of levosimendan + SFI or solely levosimendan (both P < 0.001). Alterations in BNP concentrations were not different in the combination and control groups. No differences were found between the 2 groups in heart rate or severe hypotension, but blood pressure (systolic blood pressure, diastolic blood pressure) and hemodynamic parameters including CI, cardiac output and stroke volume index responded better in the levosimendan + SFI group compared to the monotherapy levosimendan group.

conclusionsLevosimendan + SFI was superior to treat ADHF patients compared to levosimendan monotherapy and produced significant improvements in hemodynamic parameters especially for ADHF patients with hypotension. Trail registration The study was prospectively registered at Chinese Clinical Trial Registry with registration number [ChiCTR2000039385] (10/25/2020).

Indexed as

Heart FailureHypotensionPyridazinesCardiotonic AgentsDrugs, Chinese HerbalHumansHydrazonesProspective StudiesSimendanSingle-Blind MethodCardiotonic AgentsDrugs, Chinese HerbalHydrazonesPyridazinesShen-FuSimendanAcute decompensated heart failureBrain natriuretic peptideCardiorenal rescueHemodynamicLevosimendanShenfu injection

Identifiers

PMID35350988
PMCPMC8966164
OpenAlexW4221047139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.